Related Experiment Videos
A prospective study on correlation between the decrease in anti-P17 antibody level and progression to AIDS in
A M Choudhury1, O Yamada, N Wakamiya
1Department of Pathology, Research Institute for Microbial Diseases, Osaka, Japan.
Microbiology and Immunology
|January 1, 1992
Summary
Loss of anti-p17 antibody in human immunodeficiency virus (HIV) carriers indicates progression to AIDS. Identifying this marker in asymptomatic individuals can guide preventative treatments and future vaccine development.
Area of Science:
- Virology
- Immunology
- Clinical Medicine
Background:
- Human immunodeficiency virus (HIV) infection often presents an extended asymptomatic phase, necessitating identification of markers predicting disease progression.
- Understanding factors influencing the transition from asymptomatic to symptomatic stages is crucial for managing HIV carriers.
Purpose of the Study:
- To evaluate the association between virus isolation rates, anti-p17 antibody status, and progression to Acquired Immunodeficiency Syndrome (AIDS).
- To determine the predictive value of anti-p17 antibody status for AIDS development in asymptomatic HIV carriers.
Main Methods:
- Cross-sectional and prospective study involving 56 asymptomatic HIV carriers and 46 AIDS cases.
- Assessed virus isolation rates and anti-p17 antibody status in study cohorts.
- Prospective follow-up of 15 anti-p17 antibody positive and 16 negative cases for AIDS development.
Main Results:
- Progression to AIDS was significantly correlated with high virus isolation rates and loss of anti-p17 antibody.
- None of the anti-p17 antibody positive cases progressed to AIDS, whereas 6 of 16 anti-p17 antibody negative cases did (P < 0.05).
Conclusions:
- Loss of anti-p17 antibody during the asymptomatic phase is a strong indicator of impending AIDS progression.
- Monitoring anti-p17 antibody status may identify high-risk individuals needing chemoprophylaxis and inform HIV vaccine design.